A must read “masterpiece” by ... on current IO landscape of advanced RCC and bladder cancer with in-depth rationale for combining TKIs with checkpoint inhibitors with emphasis on cabozantinib. Published TODAY in MCT journal.
Good point - would refer you to a manuscript I wrote w in that underscores the rationale for a cabozantinib-based combination